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Agreement Between Quantiferon-TB Gold Test and
Tuberculin Skin Test in the Identification of Latent
Tuberculosis Infection in Patients with Rheumatoid
Arthritis and Ankylosing Spondylitis
NEVSUN INANC, SIBEL ZEHRA AYDIN, SAIT KARAKURT, PAMIR ATAGUNDUZ, SULE YAVUZ,
and HANER DIRESKENELI
ABSTRACT. Objective. To compare the Quantiferon-TB Gold test (QTF-G) with the tuberculin skin test (TST)
for the detection of latent tuberculosis infection (LTBI) among patients with rheumatoid arthritis
(RA) and ankylosing spondylitis (AS), with reevaluation of the patients treated with tumor necrosis
factor-α (TNF-α) antagonists in the followup.
Methods. The study involved 140 consecutive patients, 82 with RA and 58 with AS. Thirty patients
were evaluated with QTF-G for detection of LTBI before and after 6 months of TNF-α antagonist
treatment. QTF-G was also performed on 49 healthy controls. QTF-G results were recorded as pos-
itive, negative, or indeterminate. A positive TST was defined as ≥ 5 mm for RA and AS.
Results. The percentages of positive QTF-G were comparable in RA and AS (37% vs 32%). The rate
of positive QTF-G in healthy controls (29%) was also similar to RA and AS. In contrast to QTF-G
results, a high rate of TST positivity was observed in AS compared to RA (82% vs 55%; p = 0.02).
The total agreement between QTF-G and TST was observed to be 61% (κ = 0.29) in the whole
group, 70% (κ = 0.42) in RA, and 49% (κ = 0.14) in AS. After 6 months of treatment with TNF-α
antagonists, a high rate of QTF-G change was observed in patients with indeterminate results (23%
vs 3%; p = 0.03).
Conclusion. The comparable prevalence of LTBI among the study groups according to QTF-G sup-
ports the view that QTF-G is less susceptible to external factors than TST. Sequential testing for
QTF-G in patients with indeterminate or negative results may also be helpful in discriminating LTBI
better. (First Release Nov 15 2009; J Rheumatol 2009;36:2675–81; doi:10.3899/jrheum.090268)
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Patients with inflammatory diseases are at increased risk of
developing serious infections, mainly tuberculosis (TB).
The higher risk observed in autoimmune diseases could be
related to immune dysregulation caused by the disease itself
or to the immunosuppressive drugs used for the treatment1.
It has been observed that patients diagnosed with RA were
4 times more likely to develop TB2. A higher incidence of
Mycobacterium tuberculosis infection with the use of tumor
necrosis factor-α (TNF-α) antagonist treatments has also
been recorded in postmarketing reports3,4. The diagnosis
and treatment of latent TB infection (LTBI) in chronic
inflammatory diseases such as rheumatoid arthritis (RA)
and ankylosing spondylitis (AS) have appeared as a priority
before treatment with TNF-α antagonists, and it was sug-
gested that patients should be screened for LTBI before the
initiation of treatment with TNF-α antagonists5-7.
In recommendations for assessing the risk of LTBI and
managing it in patients due to start TNF-α antagonist treat-
ments, tuberculin skin test (TST) is one of the major ways to
determine LTBI8,9. Unfortunately, TST has serious short-
comings for the screening of LTBI. The induration threshold
values for positive TST results appear diverse (5 to 10 mm
induration)2,9. As well, there have been some concerns
about an impaired delayed-type hypersensitivity reaction to
tuberculin in patients with RA, owing either to the deficient
cell-mediated immunity of the disease itself or to treatment
with disease-modifying antirheumatic drugs (DMARD)10.
Some of the guidelines recommend a second step or a TST
booster 14 days later7. Another problem in countries where
TB is prevalent and bacillus Calmette-Guerin (BCG) vacci-
nation is routine might be false-positive TST results.
Environmental mycobacterial exposure may also lead to
false positivity11,12. Impaired TST response may cause
false-negative results, increasing the risk of TB reactivation
in candidates for TNF-α antagonist treatments, while
false-positive tests can lead to unnecessary treatment with
isoniazid, with a possibility of drug toxicity13.
In vitro interferon-γ (IFN-γ) assays that use proteins spe-
cific for M. tuberculosis have become available to detect
LTBI. One of the IFN-γ-based in vitro diagnostic tests,
which measure responses to specifically expressed ESAT-6,
CFP-10, and TB7.7 proteins by pathogenic M. tuberculosis
complex strains, is the Quantiferon TB Gold test (QTF-G;
Cellestis, South Melbourne, Victoria, Australia). It was sug-
gested that QTF-G is more accurate than TST for the diag-
nosis of active and LTBI in the general population12. The
performance of the QTF-G and other commercial assays
based on similar assay principles has been investigated in a
group of patients with inflammatory diseases and in RA14-17.
However, it is still not clear from these studies if the use of
IFN-γ-based tests instead of relying only on TST has addi-
tional benefit in reducing the rate of LTBI reactivation.
We compared a whole-blood IFN-γ assay with TST for
LTBI testing in a high-incidence country with prevalent
BCG vaccination in patients with RA and AS. The IFN-γ
responses of patients who were treated with TNF-α antago-
nists for 6 months were also reevaluated.
MATERIALS AND METHODS
Patients with RA and AS who had both QTF-G and TST were enrolled con-
secutively for the study. Eighty-two patients with RA fulfilling the 1987
American College of Rheumatology RA criteria18 and 58 patients with AS
fulfilling the modified New York criteria19 between March 2007 and June
2008 from the outpatient rheumatology clinic were recruited for the study
(Figure 1). We also included 49 healthy volunteers as control subjects for
the study. Exclusion criteria for healthy volunteers were being on the hos-
pital staff, being a patient in the hospital, and having chronic diseases
and/or immunosuppressive drug treatments. All patients in the study were
taking DMARD. Thirty of them who fulfilled recognized national criteria
for TNF-α antagonist therapy were reevaluated for latent TB with QTF-G
after taking TNF-α antagonists for 6 months. Patients were excluded from
the study if they had treatment incompliance, had acute infections, or did
not return for a TST reading at baseline and for the second control of
QTF-G at 6 months. The study was approved by the Ethical Committee of
Marmara University Medical School, and all patients gave their informed
consent.
All patients and controls were interviewed for a personal and family
history of TB. BCG vaccinations were examined and recorded. Chest radio-
graphs were performed and evaluated by a specialist in pulmonology for
the presence of any signs of TB infection (Table 1). All study participants
underwent TST after a blood sample was taken for a QTF-G test. The
Mendel-Mantoux skin test using an intradermal injection of 0.1 ml of puri-
fied protein derivative (PPD) was given, and the induration was measured
in millimeters by an experienced examiner after 72 hours of inoculation.
Boosters were performed in all patients with no response to TST. According
to the national guideline developed by the Society for Research and
Education in Rheumatology (RAED), an induration of 5 mm was consid-
ered positive for TNF-α antagonist-eligible patients. LTBI treatment was
given as necessary according to the results of the TST before TNF-α anta-
gonists were introduced.
We performed the QTF-G test, which measures responses to ESAT-6,
CFP-10, and TB7.7 proteins, on all participants in the study. QTF-G results
were considered positive, negative, or indeterminate according to manu-
facturer’s recommendations.
The concordance between TST and QTF-G was evaluated using agree-
ment and the kappa analysis. The test results were evaluated using Cohen’s
kappa (κ), with κ value > 0.75 representing good agreement, 0.4–0.75 fair
to good agreement, and < 0.40 poor agreement. The Mann-Whitney U test
was used to compare the quantitative variables in the group’s data, and the
chi-square test was performed to compare the qualitative variables. The
paired sample t test was used for the comparison of sequential test results
in the same group. Statistical analysis was performed using SPSS version
11.5.
RESULTS
Whole-group analysis. In the evaluation of the whole group
for whom both tests were available, indeterminate QTF-G
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Figure 1. Breakdown of positive test results among patients with rheumatoid arthritis and ankylosing spondylitis and healthy controls. QTF-G:
Quantiferon-TB Gold test; TST: tuberculin skin test.
results were observed in 8/140 (5.7%), and 4 of these
patients had no reaction to TST. We excluded the results of
these 8 patients from our analyses. Overall agreement
between TST and QTF-G was low, with positive or negative
concordance in 81/132 (61%) patients (κ value = 0.29). The
proportion of patients with positive tests was higher in TST
than QTF-G (66% vs 35%). A TST(+)/QTF-G(–) result was
present in 35% (46/132) while a TST(–)/QTF-G(+) result
was observed in only 4% (5/132).
When a booster was given to the patients with no
response to PPD, 25% of TST results converted to positive.
No improvement was observed in agreement between
QTF-G and TST in RA, AS, and the whole group [κ values
0.259 (p = 0.010), 0.419 (p = 0.052), 0.149 (p = 0.015),
respectively].
When we evaluated the presence of at least 1 of the risk
factors for LTBI (history of TB personally or in close rela-
tives, chest radiograph with findings of a previous TB expo-
sure) and in relation to the BCG vaccination status, we
observed fair to good agreement between TST and QTF-G
in BCG-nonvaccinated (83%, κ = 0.67), which was higher
than in the BCG-vaccinated patients (56%, κ = 0.21). The
level of agreement between TST and QTF-G was also fair to
good in the presence of one of the risk factors (82%, κ =
0.65) than in the absence of risk factors (57%, κ = 0.22).
QTF-G and TST in patients with RA. Five of 82 (6%)
patients had indeterminate results. TST positivity was high-
er than QTF-G in RA (55% vs 37%) and QTF-G positive
results of healthy controls (29%) were similar to those of
RA (37%) (Figure 1). We observed that agreement between
QTF-G and TST was moderate in RA, with negative or pos-
itive concordance in 54/77 (70%) and a κ value of 0.42
(Table 2).
Patients with positive QTF-G had increased TST meas-
urements (12.1 vs 5.1 mm; p < 0.001). Among 34 of 82
(41%) patients with no reaction to TST, QTF-G results were
negative in 26 (76%), positive in 5 (15%), and indeterminate
in 3 (11%).
Using 10 mm induration diameter as the TST cutoff
value, the agreement between the 2 tests was 57/77 (74%)
with a κ value of 0.47 (Table 3). Using 15 mm induration
diameter as the TST cutoff value, the agreement between the
tests was 51/77 (71%), with a κ value of 0.35. Comparisons
of the corticosteroid dosage, the length of corticosteroid
treatment at recruitment, and Disease Activity Score-28
joint (DAS28) score in patients with and without a
false-negative (TST- but QTF+) result have also been per-
formed. The dosage of corticosteroid at recruitment was
higher in patients with false-negative results than in patients
without false negatives (9.5 ± 6.2 vs 4.5 ± 5.0; p = 0.03).
Although longer duration of corticosteroid treatment and
higher DAS28 scores were also observed in the false-nega-
tive group, the differences were not significant.
QTF-G and TST in patients with AS. Three of 58 (5%)
patients with AS had indeterminate results. In the analysis of
patients with AS, the agreement between QTF-G and TST
was low, with concordance in 27/55 (49%) and a κ value of
0.14 (Table 2). The number of patients with AS testing pos-
itive with the TST was higher than with QTF-G (82% vs
32%) (Figure 1).
Patients with positive QTF-G showed increased TST
measurements (15.3 vs 8.9 mm; p < 0.001). Among 10 of 58
(17%) patients with no reaction to TST, QTF-G results were
negative in 8 (80%), positive in 1 (10%), and indeterminate
in 1 (10%). Using 10 mm induration diameter as the TST
cutoff value, the agreement between 2 tests was 32/55
(58%) with a κ value of 0.26 (p = 0.008; Table 3). Using 15
mm induration diameter as the TST cutoff value, the agree-
ment between the tests was 42/55 (76%) with a κ value of
0.47 (p < 0.001).
Only 1 patient with AS had a false-negative result, so the
comparison with clinical characteristics was not done.
Comparison of QTF-G and TST results in patients with RA
and AS. Positive results in patients with RA and AS were
comparable for QTF-G (37% vs 32%) but significantly dif-
ferent with the TST (55% vs 82%; p = 0.02). The percent-
age of patients with TST(+)/QTF-G(–) results was higher in
AS than RA (49% vs 25%; p = 0.004), while TST(–)/
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Age, mean, yrs (SD) 55.4 (11.2) 39.5 (11.2)
Sex (F/M) 73/9 22/36
BCG vaccinated, % 77 95
Disease related factors
Disease duration, yrs, mean (SD) 13 ± 9 12 ± 8
RF-positive, % 65 NA
HLA-B27-positive, % NA 78
DAS28 (mean ± SD) 4.8 ± 1.3 NA
BASDAI (mean ± SD) NA 27 ± 14
Treatment at recruitment
Prednisolone, % 60 5
Mean prednisolone at recruitment, mg/day 4.8 + 5.2 0.3 ± 1.3
Mean duration of prednisolone, yrs 5.0 ± 5.4 2.4 ± 15.9
DMARD only, % 70 60
DMARD and TNF antagonist, % 7 2
TNF antagonist only, % 10 17
DMARD and TNF-naive, % 13 21
New treatment with TNF antagonists, % 21 22
Risk factors for LTBI, %
History of TB infection, % 4 2
Chest radiograph suggestive of TB, % 8 6
History of TB in close relatives, % 15 11
LTBI: latent tuberculosis infection; RA: rheumatoid arthritis; AS: ankylos-
ing spondylitis; BCG: bacillus Calmette-Guerin; SD: standard deviation;
RF: rheumatoid factor; DAS28: Disease Activity Score 28-joint count;
DMARD: disease-modifying antirheumatic drugs; TNF: tumor necrosis
factor; NA: not applicable.
QTF-G(+) results were comparable. Forty-one percent of
patients with RA showed no reaction to TST (0 mm), com-
pared to 17% of patients with AS (p = 0.001). Indeterminate
results of QTF-G tests were found to be comparable
between patients with RA (n = 5) and patients with AS (n =
3; 5% vs 4%), while none of the healthy controls had inde-
terminate results.
QTF-G results after TNF-α antagonist treatment. Thirty
patients (17 RA, 13 AS) were investigated with QTF-G
before and 6 months after treatment with TNF-α antago-
nists. After treatment, 30% of the QTF-G results changed.
Five out of 7 indeterminate results changed to negative and
1 of them to positive. A statistically significant change of
QTF-G was observed in patients with indeterminate results
(23% vs 3%; p = 0.03). In 2 patients with RA, negative test
results before TNF-α antagonists converted to positive at
the sixth month. One of these patients had negative TST at
the onset of treatment with TNF-α antagonists and had find-
ings suggestive of TB in high-resolution computed tomo-
graphy scans at the sixth month. Both patients had positive
TST at the 6-month visit. Four patients with positive QTF-G
had received LTBI treatment and only 1 reversion was
detected after the sixth month.
DISCUSSION
Investigation of LTBI in patients with RA and AS is crucial,
especially in those treated with TNF-α antagonists, because
such patients are at increased risk of LTBI reactivation. In
our study, we evaluated QTF-G, a widely investigated IFN-γ
test and compared it to TST in patients with RA and AS. We
determined a comparable presence of positive test results in
patients with RA and AS with QTF-G, while a significant
difference was present with TST between the 2 diseases.
The rate of positive QTF-G test results in healthy controls
was similar in patients with RA and AS and was an encour-
aging observation for the use of QTF-G in LTBI evaluation.
In patients with RA, positive TST results using the 5 mm
cutoff were higher than the rate of positive QTF-G results
(55% vs 37%) and an overall agreement of 70% was found
between the 2 tests (κ value 0.42). Our results were consis-
tent with recent studies reporting an overall agreement of
60%–70% (Table 4). The level of agreement between
QTF-G and TST was similar with the 10 mm cutoff but
declines with the 15 mm cutoff (Table 3).
A higher number of patients with positive TST compared
to QTF-G has been detected in patients with AS (82% vs
32%). To our knowledge, this is the first study evaluating
the performance of QTF-G in comparison with TST in AS
separately. We also observed that patients with positive
QTF-G had significantly increased TST measurements in
AS. Agreement between QTF-G and TST was increased
from fair to moderate with the 15 mm cutoff, but this
increase was less obvious with the 10 mm cutoff. The low
level of agreement between TST and QTF-G might increase
if the 15 mm cutoff, which is the standard value for healthy
people in our country, is preferred (Table 3).
In our study, the percentage of patients who showed no
reaction to TST was significantly higher in patients with RA
than in patients with AS. Five of the patients with RA and 1
with AS had positive QTF-G results. A higher number of
patients with RA showed no TST reaction compared to
healthy controls in a previous study10, supporting the limi-
tations of TST, especially in immunosuppressed patients.
We investigated the association between both tests and
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Table 2. Agreement between QTF-G and TST in patients with rheumatoid arthritis and ankylosing spondylitis.
Rheumatoid Arthritis Ankylosing Spondylitis
TST (–) TST (+) Total TST (–) TST (+) Total
QTF-G (–) 29 18 47 8 27 35
QTF-G (+) 5 25 30 1 19 20
Total 34 43 77 9 46 55
Kappa 0.42 0.14
QTF-G: Quantiferon-TB Gold test; TST: tuberculin skin test.
Table 3. QTF-G positive test results according to different cutoffs for TST.
Agreement Between
TST Cut-off Values, mm TST and QTF-G (%) Kappa p
Rheumatoid arthritis ≥ 5 54/77 (70) 0.42 NS
≥ 10 57/77 (74) 0.47 NS
≥ 15 51/77 (71) 0.35 NS
Ankylosing spondylitis ≥ 5 27/55 (49) 0.14 NS
≥ 10 32/55 (58) 0.26 0.008
≥ 15 42/55 (76) 0.47 < 0.001
QTF-G: Quantiferon-TB Gold test; TST: tuberculin skin test; NS: not significant.
the factors that could be related to a deficient cell-mediated
immunity such as demographics, disease activity status, and
drug regimens. It was determined that false-negative TST
results in RA were affected by the corticosteroid dosage.
This result may reflect the effect of corticosteroids on TST
positivity and suggests that TST results might necessitate
confirmation with QTF-G. We also observed a better agree-
ment between the 2 tests in BCG-nonvaccinated than in
BCG-vaccinated patients. The annual incidence of TB is
30/100,000 according to official reports in Turkey
(www.saglik.gov.tr), and the latent TB rate is estimated to be
30%–50% of the adult population. According to Turkish
Ministry of Health guidelines for BCG vaccination, all chil-
dren should be BCG-vaccinated at 2–3 months of age and a
booster vaccination given at 6–7 years of age. However, a
repeated BCG vaccination schedule with 3 or 4 vaccinations
had been used until the last decade in Turkey. Still, studies
from different regions of Turkey have indicated that the rate
of BCG scar was only 34.6%–64.5%25. It was shown that
BCG vaccination increases the likelihood of false-positive
TST results for up to 15 years. A study by Cobanoglu, et al
showed that when comparing subjects under 25 years of age
to subjects aged older than 25 years, repeated BCG vaccina-
tions were related to high discordance between the TST and
QTF-G in subjects older than 25 years20.
A higher rate of positive TST in comparison to QTF-G in
patients with chronic inflammatory diseases was observed
in a study from Turkey20. It was reported also that false-pos-
itive results are common in BCG-vaccinated subjects, or due
to a booster effect26,27. In contrast, Ponce de Leon, et al did
not find a relationship between BCG, TST, and QTF-G10.
Several factors influencing TST response including BCG
strain used, dosage, number of vaccinations, age, and time
elapsed since vaccination have been reported.
In one study, it was observed that the performance of
QTF-G was related to the presence of risk factors for LTBI
(history of TB personally or in close relatives, chest radio-
graph with findings of previous TB exposure). The per-
formance of QTF-G seems to be better than TST for the
detection of LTBI in patients receiving immunosuppressive
drugs for systemic autoimmune diseases16. We observed a
better agreement between TST and QTF-G in the presence
of at least 1 of the risk factors for LTBI. TST may perform
better in patients with risk factors, but in patients without
any risk for LTBI, QTF-G should be preferred.
In our study, a total of 30 patients with RA and AS were
evaluated after treatment with TNF-α antagonists for 6
months. We observed that 30% of the QTF-G results
changed. This high rate of QTF-G change was especially
prominent among patients with pretreatment indeterminate
results. Among 17 patients with negative QTF-G in the
beginning, 2 converted to positive. It might be beneficial to
evaluate patients with indeterminate and negative test results
after TNF-α antagonist treatments. In this circumstance,
anti-TB treatment should be considered for the cases of QTF-
G conversion in patients with RA receiving treatment with
TNF-α antagonists. T cell reactivity, as measured by IFN-γ
production to PPD, influenza, and collagen type II, was
shown to be increased after treatment with TNF-α antago-
nists28 and this might explain the change in immune response
in our negative patients. However, a high QTF-G cutoff
value can also cause a problem, because a lower cutoff value
for QTF-G increased the sensitivity of the assay in a com-
parative study involving patients with untreated, culture-con-
firmed cavitary pulmonary TB and healthy subjects29.
There are some limitations in our study. The sample size
was not calculated before the study but all the consecutive
patients between March 2007 and June 2008 were enrolled.
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Table 4. Characteristics of LTBI studies that use QTF-G as part of a screening program in RA and other chron-
ic inflammatory diseases.
Study Study Group Positive Positive Agreement, % Kappa* Patients, n
QTF-G, % TST, %
Matulis16 RA, SpA, UA, NA NA 64 0.17 109
other
Cobanoglu20 Chronic 18 73 NA 0.18 51
inflammatory
diseases
Takahashi21 RA 28.5 28.5 NA NA 14
Greenberg17 RA 18 21.3 NA NA 61
Chen22 RA NA NA 60 0.21 35
Ponce de Leon10 RA 44.6 26.7 70.3 0.37 101
Bartalesi23 Autoimmune 13 19 87.7 0.55 398
diseases
Bocchino24 RA, PsA, UC, CD 31.8 26 NA 0.26 69
RA: rheumatoid arthritis; SpA: spondyloarthropathies; UA: undifferentiated arthritis; PsA: psoriatic arthritis;
UC: ulcerative colitis; CD: Crohn’s disease; QTF-G: Quantiferon-TB Gold test; TST: tuberculin skin test. * For
agreement between QTF-G and TST. NA: not available.
There is no gold standard for the progression of TB in
patients with positive test results and it is unethical to follow
up patients with positive test results without LTBI treatment.
We could not determine active TB in our group so we could
not evaluate the value of the results according to the out-
come. On the other hand, our results confirmed the reliabil-
ity of current guidelines for the evaluation of these patients.
We observed a higher prevalence of LTBI with TST than
QTF-G in patients with RA and AS, with the probability of
overtreatment according to TST results. As an encouraging
result for the QTF-G test, the percentage of positive results
was comparable between 2 different diseases and healthy
controls. Additionally, QTF-G may be more useful in
patients without LTBI risk factors. The possibility of con-
version of the test results with QTF-G also necessitates the
repeated evaluation of patients.
In a country with a high incidence of TB and BCG vac-
cination, the QTF-G test might help to differentiate
false-positive TST tests from latent TB infections and might
prevent overtreatment.
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